Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Appoints Dr. Amie Phinney as Director

Newsfile September 16, 2025

Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000

Newsfile September 15, 2025

Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth

Newsfile September 2, 2025

Defence Therapeutics Announces Debenture Units Financing

Newsfile August 22, 2025

Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

Newsfile July 14, 2025

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Newsfile June 9, 2025

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Newsfile June 2, 2025

Defence Therapeutics to Attend Bio International Convention in Boston, June 2025

Newsfile May 28, 2025

Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Newsfile April 8, 2025

Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer

Newsfile March 26, 2025

Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million

Newsfile January 31, 2025

Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025

Newsfile January 10, 2025

Defence Fortifies Patent Portfolio

Newsfile January 6, 2025

Defence Arranges Financing

Newsfile December 31, 2024

Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors

Newsfile December 20, 2024

Defence Provides Update on Delivery of AGSM Proxy Materials

Newsfile December 2, 2024

Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Newsfile November 29, 2024

Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development

Newsfile November 25, 2024

Defence Announces Closing of Securities for Debenture Financing

Newsfile November 22, 2024

Defence Therapeutics Announces Securities for Debenture Financing

Newsfile November 14, 2024

Podcasts